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A B S T R A C T   
Typhoid fever is a bacterial infection caused by the Gram-negative bacterium Salmonella enterica subspecies 
enterica serovar Typhi (S. Typhi), prevalent in many low- and middle-income countries. In high-income terri-
tories, typhoid fever is predominantly travel-related, consequent to travel in typhoid-endemic regions; however, 
data show that the level of typhoid vaccination in travellers is low. Successful management of typhoid fever using 
antibiotics is becoming increasingly difficult due to drug resistance; emerging resistance has spread geograph-
ically due to factors such as increasing travel connectivity, affecting those in endemic regions and travellers alike. 
This review provides an overview of: the epidemiology and diagnosis of typhoid fever; the emergence of drug- 
resistant typhoid strains in the endemic setting; drug resistance observed in travellers; vaccines currently 
available to prevent typhoid fever; vaccine recommendations for people living in typhoid-endemic regions; 
strategies for the introduction of typhoid vaccines and stakeholders in vaccination programmes; and travel 
recommendations for a selection of destinations with a medium or high incidence of typhoid fever.   
1. Introduction 
Typhoid is a bacterial infection caused by the Gram-negative bac-
terium Salmonella enterica subspecies enterica serovar Typhi (S. Typhi). 
Typhoid fever is usually contracted by ingestion of food or water 
contaminated by faecal or urinary carriers excreting S. Typhi [1]. The 
predominant symptom of infection is high fever, with other symptoms 
including nausea, abdominal pain and abnormal bowel movements [2]. 
Once prevalent worldwide, improvements in the provision of clean 
water and sewerage systems has led to a dramatic decrease in the inci-
dence of typhoid fever with the burden of disease now predominantly 
residing in low- and middle-income countries where sanitary conditions 
may be poor [1]. 
In developed countries, typhoid fever is a predominantly travel- 
associated disease [3], impacting travelling populations such as tour-
ists, military personnel, temporary workers, or travellers visiting friends 
or relatives (VFR) in endemic areas, with risk varying by the 
geographical region visited [3–6], the duration of travel, integration 
with local cultures, traveller concurrent diseases or medications. 
Successful management of typhoid fever using antibiotics is 
becoming increasingly difficult due to drug resistance [7,8]; emerging 
resistance has spread geographically due to factors such as increasing 
travel connectivity, affecting those in endemic regions and travellers 
alike. 
The aim of this article is to provide an overview of: the epidemiology 
and diagnosis of typhoid fever; the emergence of drug-resistant typhoid 
strains in the endemic setting; drug resistance observed in travellers; 
vaccines currently available to prevent typhoid fever; vaccine recom-
mendations for people living in typhoid-endemic regions; strategies for 
the introduction of typhoid vaccines and stakeholders in vaccination 
programmes; and travel recommendations for a selection of destinations 
with a medium or high incidence of typhoid fever. 
Abbreviations: AE, adverse event; CI, confidence interval; Ig, immunoglobulin; MDR, multidrug resistance/resistant; PCR, polymerase chain reaction; S. Typhi, 
Salmonella enterica subspecies enterica serovar Typhi; TCV, typhoid conjugate vaccine; TMP-SMX, trimethoprim-sulfamethoxazole; UDP, uridine-diphosphate; VFR, 
travellers visiting friends or relatives; Vi-CRM197, Vi polysaccharide conjugated with CRM197; Vi-DT, Vi polysaccharide conjugated to diphtheria toxoid; ViPS, Vi 
polysaccharide; Vi-rEPA, Vi polysaccharide bound to the recombinant exoprotein of Pseudomonas aeruginosa; XDR, extremely drug resistant; WHO, World Health 
Organization. 
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2. Methodology 
An original literature search was conducted on March 19, 2019 in 
PubMed and EmBase, limited to English-language articles and studies of 
human individuals. The search terms were ‘Typhoid [Title] AND resi-
stan*[Title]’, limited to the last 15 years, and ‘Typhoid [Title] AND 
vaccin* [Title/Abstract] AND resistan* [Title/Abstract]’, limited to the 
last 20 years. Reference lists of relevant articles were also screened to 
identify other additional sources. Apart from abstracts listed in EMBASE, 
grey literature (e.g. government resources and congress publications) 
was not included, and duplicate articles were removed. The search re-
sults were screened by a non-blinded reviewer to exclude articles that 
did not provide information about typhoid in humans. Possible articles 
of interest were retrieved, reviewed and relevant data extracted. Dual 
validation was not performed as the intention was not to provide a 
quantitative meta-analysis. Owing to the time since the original search 
was run, the literature included in this review was updated in the week 
commencing November 16, 2020 and relevant additional literature 
added. 
3. Overview of the epidemiology of typhoid fever 
An estimated 26.9 million episodes of typhoid fever occur annually 
worldwide (interquartile range 18.3–35.7 million) [9], although precise 
estimates are difficult to establish. This is due to the non-specific pre-
senting symptoms and signs, under-reporting of cases (screening pro-
cedures are not undertaken if the patient is asymptomatic), and lack of 
suitable diagnostics in many regions (see section 3.1 “Diagnosis of 
typhoid fever”). The highest burden of typhoid fever is thought to be on 
the Indian subcontinent, however there is considerable heterogeneity in 
the distribution of typhoid fever [10]. In sub-Saharan Africa, the inci-
dence of typhoid has historically been poorly described [11]. Indeed, 
data from the Typhoid Surveillance in Africa Program and other groups 
have shown that the incidence in African regions may be as high as (or 
exceed) that in Asia [12–14], affecting both rural and urban populations 
[14,15]. 
At the regional level, modelling data from Antillon and colleagues 
estimate that the incidence of typhoid fever in the Eastern sub-Saharan 
Africa region could be 620 cases per 100,000 person-years (95% confi-
dence interval [CI] 213–2921), approximately three-fold higher than the 
Southeast Asia region (217 cases per 100,000 person-years; 95% CI 
88–571) [13]. An analysis by the GBD 2017 Typhoid and Paratyphoid 
Collaborators estimated that, in 2017, South Asia had the highest 
age-standardised incidence rate (549 [481–625] cases per 100,000 
person-years) and the largest number of cases (10.3 million [9.0–11.7]), 
accounting for 71.8% of global cases, while the sub-Saharan Africa re-
gion accounted for 12.1% (1.73 million [1.45–2.06]) of global cases 
(Fig. 1) [16]. A multicentre population-based prospective study across 
13 sites in 10 African countries highlighted that children aged 2–14 bear 
the greatest burden of typhoid fever [17]. The degree of uncertainty is 
considerable in regions where typhoid surveillance is weak or 
non-existent [13], emphasising the importance of capturing 
wide-ranging surveillance data to fully understand typhoid incidence 
and the likely outcome of different interventions. 
Fig. 1. Incidence rates (per 100,000) of typhoid and paratyphoid fevers, by country, in 2017. Reproduced with permission, Copyright © 2019 The Author(s). 
Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license [16]. 
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Along with paratyphoid fever (caused by Salmonella enterica sub-
species serovar Paratyphi A, Paratyphi B and Paratyphi C), typhoid fever 
is a type of enteric fever [18]. S. Typhi is estimated to cause 76.3% (95% 
CI 71.8–80.5) of cases of enteric fever globally in 2017, with an esti-
mated mean all-age global case fatality of 0.95% (95% CI 0.54–1.53), 
with higher fatality among children and older adults, and among those 
living in low income countries [16]. 
During the course of infection, carriage can be split into three periods 
– convalescence, temporary and chronic [19]. As many as 10% of 
convalescent carriers shed bacilli in faeces for up to 3 months 
post-infection [1]. Following resolution of the disease, approximately 
1–4% of typhoid patients progress to the carrier state, excreting the 
bacilli for more than 1 year [1]. Typhoid fever-causing Salmonella have 
no known environmental reservoir, but it is thought that the chronic 
asymptomatic carrier is responsible for continued maintenance of the 
bacteria within human populations [19]. The carrier state has not been 
extensively studied as the majority of chronic carriers in endemic set-
tings are asymptomatic [1] and a substantial proportion may have had 
no clinical history of typhoid [19]. However, it is known that chronic 
carriage is more common in women and increases with age [20]. It is 
likely that breach of the intestinal epithelial barrier, evasion of early 
innate immune-mediated killing, and localisation to the biliary tract and 
gallbladder are requirements for development of the carrier state [19]. 
Approximately 90% of carriers present with gallstones [21]. Mechanistic 
studies have shown that S. Typhi forms biofilms on gallstones [22], the 
formation of which is proposed to aid in their survival and persistence 
during this phase of the transmission cycle [23]. 
Recent outbreaks, such as the ongoing outbreak in Zimbabwe (active 
since 2017), demonstrate how poor sanitation and overcrowding are 
drivers of seasonal outbreaks of typhoid fever and other waterborne 
diseases [24]. In addition to water-related and socio-economic risks, 
improper food handling is a risk factor [25,26], underlying the impor-
tance of detecting index cases to allow education (and vaccine strate-
gies) to be appropriately targeted. 
Typhoid fever is extremely uncommon in countries that have access 
to treated water supplies and sanitation systems that remove human 
waste [27]. In non-endemic regions, typhoid is a predominantly 
travel-associated disease [28–33]. In 2016, 22 countries from the EU 
reported over 1100 cases (typhoid and paratyphoid combined), with 
France, Italy and the UK accounting for approximately 70% of those 
cases [33]. Of those with available information, 82.5% were 
travel-related, with India and Pakistan accounting for the majority of 
cases [33]. In the USA, 79% (240/303) of typhoid fever patients trav-
elled or lived outside of the country in the 30 days prior to illness [31]. 
Previously it was estimated that the incidence of typhoid among trav-
ellers to a selection of low- and middle-income countries was ≤1 case 
per 100,000 travellers, except for those who visited Nepal or India 
where the case rate was 7.9 or 27–81 cases per 100,000 travellers, 
respectively [3]. The most common reason to travel abroad for patients 
who subsequently contracted typhoid fever was to visit friends or rela-
tives [29,31,33]. The literature suggests that VFR are at higher risk of 
contracting travel-related illness, compared with other groups of trav-
ellers, due to factors including an increased likelihood of travelling for 
longer periods of time, travel to rural destinations and being more likely 
to drink untreated water [34]. Additionally, as VFR may co-habit with 
their friends and family, they may have greater exposure to asymp-
tomatic carriers in the endemic population (and possibly experience 
lower levels of sanitation in the home setting), contributing to their 
increased risk of typhoid fever compared with other travellers. 
Another group of travellers potentially at risk of typhoid are military 
personnel deployed to typhoid-endemic regions. A review of the typhoid 
fever cases reported in the US military (1998–2011) revealed 205 cases 
of typhoid fever among military service members, for an incidence of 
1.09 per 100,000 person-years, consistent with the incidence of typhoid 
in the general US population during that same time period, the majority 
of which was travel-related [35]. Increases in deployment of military 
personnel to countries with medium or high incidence estimates could 
be expected to increase the risk of typhoid fever, however this has not 
been shown, in part due to deployed troops not experiencing the living 
conditions of the local population [35]. 
The risk of acquiring typhoid increases with the duration of stay. 
Correspondingly, in a study of travellers from Greece to typhoid- 
endemic areas (such as sub-Saharan Africa and Southeast Asia), it was 
shown that typhoid vaccine administration is statistically associated 
with the duration of stay [36] as travellers look to mitigate their risks. 
Approximately 20% of travellers who stayed <1 month underwent 
vaccination compared with nearly 35% who stayed ≥6 months [36]. 
However, data show that typhoid fever is a risk even for short-term 
travel – 5% (31/626) of travellers from the USA with typhoid fever re-
ported that their travel outside of the USA lasted ≤1 week compared 
with 60% (376/626) whose travel lasted ≤6 weeks [37]. Therefore, 
behaviours and expected exposure to typhoid fever at the destination 
should be considered, not only the length of travel. 
Travellers who acquire typhoid fever are rarely immunised. Previous 
data of travellers who developed typhoid fever show that just 4% (36/ 
1027) reported having received a typhoid vaccination at any point 
during the previous 5 years preceding travel [37]. Data from the US 
military revealed that 26% (53/205) of military personnel had a docu-
mented S. Typhi vaccination within 2 years of typhoid fever diagnosis 
[35]. More recent data of young Canadian travellers with typhoid fever 
revealed that 0% (0/39) had a record of typhoid vaccination [30]. This 
low rate of vaccination is therefore one of the key factors that contribute 
to the occurrence of typhoid infection in travellers [30,37]. 
3.1. Diagnosis of typhoid fever 
Isolation of S. Typhi from blood is the current gold standard for 
determining typhoid fever infection [38]. Bacterial culture from bone 
marrow is more sensitive but is difficult to obtain, invasive and is 
impractical for routine use [38]. Although blood cultures remain the 
gold standard for diagnosis, this method has poor sensitivity [38]. In 
addition, culturing takes at least 48 h to generate results, and optimal 
usage is hampered by lack of healthcare infrastructure and adequately 
trained laboratory personnel in resource-limited countries where 
typhoid fever is common [38,39]. 
The Widal test is a serological test that detects agglutinating anti-
bodies against the O and H antigens [38]. It is widely used due to its 
simplicity and low cost [38] but has low sensitivity [40] and is highly 
operator dependent [41], with values varying considerably between 
geographical areas [1]. In addition, the background level of antibodies 
in a normal healthy population within a typhoid-endemic region means 
that proper interpretation of the Widal test results entails collection of 
sera from two visits (spaced 10–14 days apart) and requires each 
country to determine the appropriate antibody titre with which to di-
agnose typhoid [39,42], since there is no universal titre cutoff to define 
the disease. With the emergence of antibiotic resistance (see Section 4, 
“Overview of the treatment of typhoid fever and the emergence of 
drug-resistant typhoid strains”), the Widal test is inadequate as it does 
not provide susceptibility results [43]. 
Nucleic acid amplification tests, including conventional polymerase 
chain reaction (PCR), nested, multiplex and real-time PCR, have been 
developed for the detection of S. Typhi DNA in blood [39]. The main 
challenges preventing widespread use in low-resource settings are the 
high costs associated with this technology [39]. 
There are several commercially available typhoid rapid antibody 
tests that can generate results in as little as 2 min [44] allowing prompt 
treatment with antimicrobials for those with a positive result. One 
qualitative test, Typhidot®, uses pre-dotted antigen strips to detect the 
presence of immunoglobulin (Ig)M and -G antibodies to an outer 
membrane protein [44]. A semi-quantitative colourimetric test (IDL 
TUBEX® TF) relies on visual and subjective examination of colour re-
actions to detect anti-O:9 antibody titres [44]. However, in comparative 
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studies of performance utilising blood culture as the comparator, this 
type of testing can perform poorly [44]. A recent meta-analysis reported 
an average sensitivity of 78% (95% CI 71–85; the ability to identify true 
positives) and specificity of 87% (95% CI 82–91; the ability to identify 
true negatives) for TUBEX [38]. Analysis of all Typhidot variants as a 
group showed an average sensitivity of 84% (95% CI 73–91) and spec-
ificity of 79% (95% CI 70–87) [38]. A recent study conducted in Ban-
gladeshi patients revealed that the sensitivity of typhoid rapid antibody 
tests may be as low 60.2% (95% CI 49.3–71.2) and 59.6% (95% CI 
50.1–69.3), respectively [45]. These results emphasise the difficulties of 
laboratory diagnosis of typhoid. 
At present there is no gold standard for the detection of chronic 
typhoid carriers. Standard practice has been to detect typhoid carriage 
through serial analysis of stool and urine samples (using culturing), 
however this is logistically challenging and suffers from low sensitivity 
[19]. 
The presenting signs and symptoms of typhoid fever are shared with 
other febrile illnesses (such as malaria, dengue or other arbovirus fevers) 
[46], and thus differentiating S. Typhi infection from other sources of 
fever in endemic areas is a diagnostic challenge [38]. In most endemic 
areas (at least in Africa), the only means for diagnosis of a febrile patient 
is the Widal test for typhoid fever or the thick blood smear for malaria 
and, as has been shown, the Widal test performs poorly. The lack of 
diagnosis (because tests are not ordered), misdiagnosis (due to the use of 
insensitive methods), poor surveillance and inadequate healthcare 
infrastructure are common problems in resource-limited settings. New 
strategies that are specific, sensitive, scaleable and cost-effective are 
required to correctly identify both acute sufferers and chronic carriers of 
typhoid, in order to stop expansion of the disease and determine the real 
global burden of S. Typhi. 
For patients in countries where typhoid is not endemic, determina-
tion of the patient’s travel history is crucial [1]. 
4. Overview of the treatment of typhoid fever and the 
emergence of drug-resistant typhoid strains 
The treatment of typhoid fever normally consists of antibiotics [1, 
11]; early initiation of effective antimicrobial therapy has been shown to 
shorten the duration of the illness and reduce the risk of complications 
and death [47]. Because of the high risk of morbidity and mortality if left 
untreated [48], clinicians may administer antibiotics to patients in the 
absence of a confirmed diagnosis (on the clinical suspicion of typhoid 
fever). However, large surveillance studies from Asia and Africa indicate 
that only 1–4% of people with suspected typhoid actually have 
culture-confirmed typhoid [49], which suggests that there might often 
be substantial overtreatment with unnecessary antibiotics. 
One of the effects of empiric prescribing of antimicrobials has been 
an increase in selective pressure on S. Typhi [49,50]. Since 1948, when 
the efficacy of chloramphenicol to treat typhoid was discovered, there 
has been a pattern of antibiotic usage and resultant development of 
resistance to antimicrobial therapies [7]. Subsequently, antimicrobial 
resistance has become a major threat to the treatment of typhoid with 
increasing levels of treatment failure [7,8] (Fig. 2). 
Multidrug resistance (MDR) is historically used to describe combined 
resistance to the first-line antibiotics chloramphenicol, co-trimoxazole 
(trimethoprim-sulfamethoxazole) and ampicillin [2]. S. Typhi can 
harbour complex MDR elements, either on self-transmissible plasmids 
carrying a cassette of antimicrobial resistance genes [51], or integrated 
into the chromosome (which is more common than previously thought) 
[52]. While antibiotic selection maintains resistance genes on the 
plasmid, there also appears to be competition between plasmids 
encoding the same resistance phenotype [53]. 
MDR S. Typhi is now considered endemic in many developing 
countries, especially in areas of South and Southeast Asia [2], mediated 
by the dissemination of the specific H58 lineage across Asian and African 
countries [8]. As with the disease incidence, antimicrobial agent sus-
ceptibility patterns vary geographically [54]. High incidences of MDR S. 
Typhi are found in areas with a high burden of typhoid, particularly in 
children aged under 15 years [55]. There is a paucity of data on the 
geographical distribution, incidence and phylogenetics of MDR S. Typhi 
in sub-Saharan Africa [55], however the H58 clade of S. Typhi is asso-
ciated with the MDR phenotype [56] and with much of the typhoid 
occurring in the last decade in East and Southern Africa [54]. 
Longitudinal studies show that the proportion of MDR strains 
decrease over time as clinicians respond to resistance and use alternative 
drugs [57]. Correspondingly, MDR S. Typhi is on the decline in South 
and Southeast Asia, because of the reduced usage of these first-line drugs 
in this region [54]. 
In response to the development and spread of MDR S. Typhi, the use 
of fluoroquinolones, (ciprofloxacin, ofloxacin, fleroxacin and peflox-
acin) became widely accepted as an alternative to treat typhoid fever 
[2]. However reports of decreased susceptibility to fluoroquinolone soon 
followed both in endemic areas and in travellers returning from such 
areas [2]. In areas with a high prevalence of both MDR and fluo-
roquinolone resistance, azithromycin (an azalide antimicrobial) and 
extended-spectrum cephalosporins (e.g. ceftriaxone) tend to be used for 
treatment [2]. 
The first outbreak of an extremely drug resistant (XDR) H58 clone 
Fig. 2. History of antibiotic efficacy studies and the emergence of antimicrobial resistance in Salmonella typhi. Abbreviations: MDR; multidrug resistant; TMP-SMX, 
trimethoprim-sulfamethoxazole. Strains noted to be “nonsusceptible” are intermediately or fully resistant. Reproduced with permission, copyright © 2018 Andrews 
et al. [7]. 
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harbouring resistance to not only the three first-line drugs (chloram-
phenicol, co-trimoxazole and ampicillin), but also fluoroquinolones, and 
extended-spectrum cephalosporins, began in Sindh province, Pakistan in 
2016 [43,58,59]. All of the XDR isolates belonged to the H58 clade and 
it is thought that the plasmid conferring resistance originated in 
Escherichia coli and was acquired by an MDR H58-endemic S. Typhi 
clone in Pakistan [43]. This outbreak resulted in 5372 XDR S. Typhi 
cases reported from 2016 to 2018 [60]. First reported in June 2019, 
several areas of Sindh province are again suffering from an outbreak of 
typhoid, with two child deaths and illness in more than 150 people 
already recorded. Thus far, five of 51 typhoid cases have been reported 
as XDR, with results of several other cases awaiting. Health authorities 
are planning to launch a mass vaccination drive to gain control of this 
current outbreak [61]. Where patients experience resistance to all first- 
and second-line drugs, the carbapenems (e.g. imipenem, meropenem 
and ertapenem) and tigecycline are considered potential alternatives 
[2]. 
In addition to the difficulties of ensuring patients receive effective 
treatment, there are also cost implications associated with resistance: 
the cost of therapy for resistant cases can be approximately 70% greater 
than the cost of sensitive typhoid cases, driven mostly by an increase in 
physician and nursing care [62]. Even with appropriate treatment, the 
risk of relapse remains, with approximately 5–10% of immunocompe-
tent patients relapsing [63]. Typhoid relapse cases have been reported in 
typhoid-endemic countries and in travellers returning from those re-
gions [48,63,64]. In one small study from India, patients with 
drug-resistant typhoid who initially received ineffective therapy had a 
higher relapse rate following effective treatment compared with those 
infected with pan-sensitive strains [63]. 
For the treatment of chronic carriers, eradication has been achieved 
with some success using ampicillin or amoxicillin, sometimes combined 
with probenecid or co-trimoxazole (dependent upon the susceptibility of 
the strain) [2]. A small study of 12 chronic S. Typhi carriers revealed a 
92% cure rate with a 4-week regimen of fluoroquinolones (ciprofloxacin 
orally twice a day for 28 days) [65]. At present, there are few data on 
this subgroup and more research is necessary to determine the best 
approach for treatment. 
4.1. Drug-resistance in travellers 
Resistance to antibiotics has been observed in travellers from non- 
endemic regions with typhoid fever, with patterns reflecting the con-
ditions in typhoid-endemic countries. Case reports of travellers return-
ing to Spain from Guatemala [66], and to Germany from Iraq [67], have 
documented infections of an extended-spectrum beta 
lactamase-producing S. Typhi strain. 
Data gathered in the USA from the National Typhoid and Para-
typhoid Fever Surveillance System and National Antibiotic Resistance 
Monitoring System revealed that antimicrobial resistance was common 
[68]. Among S. Typhi isolates, 314 (29%) were susceptible to all clini-
cally relevant antimicrobial agents, 750 (69%) were resistant to nali-
dixic acid or had decreased susceptibility to ciprofloxacin, 127 (12%) 
were MDR, and 108 (10%) were both nalidixic acid resistant/decreased 
susceptibility to ciprofloxacin and MDR [68]. Isolates resistant to nali-
dixic acid (a synthetic quinolone that is a marker of decreased suscep-
tibility or resistance to fluroquinolones) originated mainly in southern 
Asia whilst MDR cases originated from southern Asia and Africa [68]. 
The afore-mentioned typhoid fever outbreak of 2016–2018 in Sindh 
province resulted in five travel-related cases in children visiting relatives 
in Pakistan and returning to the USA [69], and one in the UK [43]. In 
April 2019, a ceftriaxone-resistant S. Typhi case was detected in a 
pregnant woman returning to Denmark from a family visit to Sindh 
province [70]. In August 2019, the first case of XDR typhoid was re-
ported in Australia [71]. 
Collectively, the occurrence of resistant cases necessitates height-
ened vigilance and re-consideration of treatment strategies for those 
who have visited a region that has high levels of antimicrobial resis-
tance. S. Typhi is quickly able to acquire new resistance mechanisms. As 
long-distance travel becomes more accessible and migration between 
endemic and non-endemic regions increases, access to information 
regarding local and regional susceptibility is important to guide 
empirical treatment [10]. Consequently, the landscape of resistance is 
dynamic. The World Health Organization (WHO) has recommended that 
the surveillance of typhoid fever be strengthened, including surveillance 
to monitor known resistance, detect new and emerging resistance, and 
mitigate its spread [72]. 
5. Vaccines available for typhoid 
To stop the expansion of typhoid, interventions should mostly focus 
on prevention. Along with improvements in antibiotic stewardship, 
public sanitation, availability of clean drinking water, safe food 
handling practices and public health education, vaccination in endemic 
areas is one strategy to prevent typhoid fever. The WHO recommends 
programmatic use of typhoid vaccines for the control of typhoid fever 
[73]. 
Two typhoid vaccines are widely available – Vivotif® (Emergent 
BioSolutions), an enteric-coated capsule formation of the live attenuated 
Ty21a vaccine, and TYPHIM Vi® (Sanofi Pasteur), a liquid formulation 
of the unconjugated Vi polysaccharide (ViPS) vaccine [74,75]. Other 
vaccines available include the combination typhoid-hepatitis A vaccine 
VIVAXIM® (Sanofi Pasteur) [76]. There are also two newer generation 
ViPS-tetanus toxoid conjugate vaccines (typhoid conjugate vaccines 
[TCVs]) currently licensed, Typbar-TCV™ (Bharat Biotech) and Ped-
aTyph™ (Bio-Med) [77,78]. Selected vaccines are summarised in 
Table 1. 
5.1. Ty21a vaccine 
The Ty21a vaccine was developed by chemical-induced mutagenesis 
of the S. Typhi Ty21 strain, resulting in a galE mutant and the inability to 
express the Vi polysaccharide antigen [109]. Inactivation of the galE 
gene generates a lack of uridine-diphosphate (UDP)-galactose-4-epi-
merase [110], which is responsible for the conversion of UDP glucose 
into UDP galactose. Consequently, there is intracellular accumulation of 
galactose derivatives and subsequent bacterial lysis, thus eliminating 
virulence of the vaccine strain [110,111]. Lipopolysaccharide synthesis 
is preserved [109]. 
S. Typhi is an intracellular bacterium and thus needs T cell- 
dependent immunological response for resolution [112]. Vaccination 
with Ty21a activates a broad immune response, with both humoral and 
systemic cell-mediated immune responses. The serum antibody response 
to Ty21a is a rise in serum IgG antibody against the O polysaccharide of 
S. Typhi [113]. Data have shown that the rate of seroconversion of IgG 
anti-O antibodies increases as more doses are administered within a 
period of 7 days [88] and that the humoral response is dose-dependent 
[114]. 
Following oral immunisation, mucosal antibody responses have been 
reported. Vaccination studies in healthy adult volunteers have revealed 
that oral Ty21a immunisation results in an increase in the concentration 
of IgG anti-lipopolysaccharide [115,116] as well as an increase in levels 
of faecal IgA (total and/or specific) [115–117]. Data have also shown 
that after oral vaccination antibody-secreting cells that produce specific 
IgA to S. Typhi O-polysaccharide bear homing receptors which commit 
them to migrate to the intestinal mucosa [118]. Cell-mediated responses 
include contributions from CD4+ helper T cells and CD8+ cytotoxic T 
cells [27]. 
In the late 1980s–1990s, a series of large-scale randomised, double- 
blind, controlled field trials (pre-licensure) of Ty21a efficacy were 
conducted assessing different dosage regimens (single or multiple 
doses), dosing intervals and formulations. The evidence from the trials 
that assessed the dosing regimen currently recommended for the Ty21a 
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Table 1 











Formulation  • Enteric-coated capsules [74]  • Liquid [75]  • Liquid [77]  • Liquid [78] 
Type  • Live attenuated Ty21a strain of  
S. Typhi [74]  
• Purified Vi capsular polysaccharide 
from the Ty2 S. Typhi strain [75]  
• Vi polysaccharide conjugated 
with nontoxic tetanus toxoid 
carrier protein [77]  
• Purified Vi capsular 
polysaccharide from the Ty2 
S. Typhi strain conjugated 




• Oral [74]  • Injectable  
• Intramuscular [75]  
• Injectable  
• Intramuscular [77]  
• Injectable  
• Intramuscular [78] 
Recommended 
dose/regimen  
• Three dose regimen, taken on 
alternate days [74]  
• Four dose regimen in USA and 
Canada [79]a  
• Entire vaccination schedule to be 
completed at least one week prior to 
travel to endemic area [74]  
• One dose [75]  
• Optimum antibody protection may be 
reached 2 weeks after administration 
[75]  
• One dose [77]  
• Prevention is effective 2–3 
weeks after immunisation [77]  
• One dose [78]  
• Prevention becomes effective 





Randomised, double-blind placebo- 
controlled field study [80,101]  
Vivotif vaccination arm: n = 22,170 
school-children, aged 6–21, three doses.   
• Year 1: 71% (95% CI 35–87)  
• Year 2: 61% (95% CI 12–82)  
• Year 3: 67% (95% CI 47–79)  
• Total years 1–3: 67% (95% CI 47–79) 
Additional follow-up   
• Years 1–7: 62% (95% CI 48–73)  
• Years 4–7: 61% (95% CI 34–73) 
Randomised, double-blind placebo- 
controlled field study [87].b  
Vivotif vaccination arms: n = 34,696 
school children, aged 5–19, three doses   
• Year 3: 33.2% (95% CI 0–57) 
Randomised, double-blind placebo- 
controlled field study [82]. TYPHIM Vi 
vaccination arm: n = 3457 individuals, 
aged 5–44   
• 17 months post-vaccination: 75% 
(95% CI unreported) 
Randomised, double-blind placebo- 
controlled field trial [83,84] TYPHIM 
Vi vaccination arm: n = 5692 children, 
aged 
5–15/16c   
• Year 1: 61% (95% CI 6–82)  
• Year 2: 52% (95% CI 5–76)  
• Year 3: 50% (95% CI 0–78)  
• Total years 1–3: 55% (95% CI 30–71) 
Randomised human challenge 
study [85] 
Typbar-TCV vaccination arm: n =
37 healthy adult volunteers, aged 
18–60, one dose   
• 72 h post-challenge: 87.1% 
(95% CI 47.2–96.9) 
Randomised controlled Phase 3 
trial [104] 
Typbar-TCV vaccination arm: 10, 
005 individuals, aged 9 
months–16 years, one dose   
• Year 1: 81.6% (95% CI 
58.8–91.8) 
Cluster randomised field study 
[86] 
Mitra, 2015, Kolkata, India. 
PedaTyph vaccination arm: n =
905 school children, aged 6 
months–12 years, one or two 
doses 
Two dosed   
• Year 1: 100% (95% CI 
97.6–99.5) 
Revaccination  • 3 years following the most recent 
vaccination for all individuals [74]  
• 3 years under conditions of repeated 
or continuous exposure [75]  
• Booster dose may be given after 
3 years [77]  
• Booster dose may be given 
from 2.5 to 3 years [78] 
Indirect (herd) 
protection  




• Moderate protection against 
paratyphoid B fever (efficacy 49% 
95% CI 8–73) [89]  
• No [75]  • No [77]  • Unknown [78] 
Recommended 
target age for 
vaccination 
Highest level of recommendation: 2b   
• Indicated for use in adults and 
children >5 years of age [74] f 
Highest level of recommendation: 2b   
• Adults and children ≥2 years of age 
[75] 
Highest level of recommendation: 4   
• Adults and children ≥6 months 
to ≤45 years of age [77] 
Highest level of recommendation: 
4   
• Children of all age groups 
from 6 months to 12 years of 
age [86] 
Safety Post-marketing surveillance [90] 
Most common AEs reported in the USA, 
July 1990–June 2002g   
• Diarrhoea (n = 51), nausea (n = 47), 
fever (n = 42), abdominal pain (n =
42), headache (n = 31), rash (n = 26), 
vomiting (n = 21), pain (n = 20), 
asthenia (n = 17), myalgia (n = 17) 
Monographh [75] 
TYPHIM Vi vaccination arm: children 
aged 12–144 months (n = 175) and 
adults aged 18–40 years old (n = 152)   
• No serious or unusual side effects in 
either children or adults 
Post-marketing surveillance [90] 
Most common AEs reported in the USA, 
July 1990–June 2002&   
• Fever (n = 11), headache (n = 11), 
dizziness (n = 9), rash (n = 9), 
urticaria (n = 9), myalgia (n = 6), 
pain (n = 6), abdominal pain (n = 6), 
pruritis (n = 6), injection site pain (n 
= 5) 
Human challenge study [85] 
Typbar-TCV vaccination arm: 
adults, n = 41   
• No serious adverse events 
related to vaccine 
administration 
Randomised, double-blind Phase 3 
study [92] 
Typbar-TCV vaccination arm: 
children and adults, n = 667   
• No serious adverse events 
related to vaccine 
administration 
Adverse event reporting during mass 
vaccination campaign [105] 
Typbar-TCV vaccination arm: 
children aged 6 months–10 years, 
n = ~207,000   
• Significantly higher rate of AEs 
in children aged 6–12 months 
vs those aged 2–3 years (0.54% 
Randomised comparative trial 
[91] 
PedaTyph vaccination arm: 
children aged 3 months− 5 
years, n = 400   
• Non-severe and recoverable 
reactions within 48 h  
• One dose, n = 400, ≥1%: 
erythema (1.5%), induration 
(1%), fever (13%), lethargy 
(1.5%)  
• Two dose, n = 168, ≥1%: 
erythema (2%), fever (18%), 
lethargy (1%) 
(continued on next page) 
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vaccine is presented in Table 1 and briefly described below. A large-scale 
randomised, controlled field trial in Santiago, Chile was performed in 
which school children (n = 22,170) received three doses of Ty21a, taken 
orally every other day, or placebo [80,101]. Results indicated that this 
regimen confers long-lived protection with 3-year efficacy of 67% [80]. 
With 7 years’ follow-up, efficacy was 62% [101]. Vaccine efficacy 
increased with age at the time of vaccination, from 59% (95% CI 16–80) 
in children aged 5–9 years, to 67% (95% CI 35–83) in those aged 10–14, 
and 85% (95% CI 42–96) in those ≥15 years old [80]. In another study, 
analysis of efficacy by age showed increased efficacy in children ≥10 
years versus those aged 5–9 years (53.5% [95% CI 7–77] vs 16.9% [95% 
CI 0–53]) [87]. The justification for the four-dose regimen employed in 
the USA and Canada originates from a large randomised field study of 
Chilean school children, which assessed the comparative efficacy of a 
two-, three- or four-dose regimen of Ty21a [81]. The incidence of 
typhoid fever in recipients of two or three doses was significantly higher 
than in those who received four doses (48% vs 40%, p < 0.002) [81]. A 
subsequent analysis of vaccine efficacy, using data from the two-dose 
group as standard, reported efficacy of 13% (95% CI 0–33; years 1–3) 
for those who received three doses and 48% (95% CI 29–62; years 1–3) 
for those who received four doses [88]. 
The effectiveness of public health vaccination programmes can 
depend on both the vaccinated and unvaccinated population. Herd 
protection is the reduction in infection or disease in the non-immunised 
proportion of the population as a result of vaccination in another pro-
portion of the population [119]. Evidence that Ty21a can provide in-
direct herd immunity comes from a field trial in Santiago, Chile, that 
used one or two doses, during which the incidence of typhoid fever in 
the control group fell during the follow-up period [102]. The incidence 
rate in the randomised placebo group in the first year of surveillance was 
227 cases per 100,000 school children [102]. The incidence in the sec-
ond year fell to 139 cases per 100,000 school children [102]. The data 
suggest that large-scale vaccination appears to cause indirect herd im-
munity in non-vaccinated subjects [88]. 
Data regarding co-administration with malaria prophylaxis were 
determined using the previously developed liquid formulation, rather 
than the capsule formulation in current usage, and suggested that the 
vaccine can be administered concurrently with malaria prophylaxis 
using atovaquone/proguanil [120]. Current manufacturer recommen-
dations state that vaccination should be completed prior to malaria 
prophylaxis, with an interval of at least 3 days between the last dose of 
vaccine and the start of malaria prophylaxis [74]. 
Ty21a can be administered to immunologically stable HIV-positive 
individuals (CD4% >25% for children aged <5 years or CD4 count 
≥200 cells/mm3 if aged ≥5 years) [73,121]. Ty21a is not recommended 
for individuals with a known depression of cell-mediated immunity 
[73]. Ty21a may be given concurrently with the yellow fever vaccine, 
CVD 103-HgR cholera vaccine and oral polio vaccine [74]. No data are 
available regarding the interaction with other live attenuated vaccines. 
Due to the potential inhibition of the growth of the vaccine organ-
isms and potential attenuation of the immune response, vaccination 
with Ty21a should be postponed during, and for at least 3 days before 
and after, antibiotic or antibacterial sulphonamide treatment [74]. For 
longer-acting antibiotics, eg azithromycin, a longer postponement 
should be considered [74]. 
At present there are no data on the safety and immunogenicity of any 
of the typhoid vaccines in pregnant or lactating women [122]. Gener-
ally, live vaccines, and therefore Ty21a, should not be given during 
pregnancy due to theoretical safety concerns [122], however the 
manufacturer suggests that it could be administered in cases of increased 
risk of infection [74]. 
The efficacy trials of the three- or four-dose alternate-day regimen 
did not specifically include safety monitoring. However, safety of the 
Ty21a vaccine can be assessed from post-marketing surveillance data. 
Post-marketing surveillance data collected in the USA through the 
Vaccine Adverse Event Reporting System (July 1990 to June 2002; four- 
dose regimen) revealed 345 reports of adverse events (AEs) related to 
the administration of Ty21a alone or in combination with other vaccines 
[90]. The rate of AEs or serious AEs was 9.7 or 0.59 per 100,000 doses, 
respectively and AEs included diarrhoea, nausea, fever and abdominal 











and 0.33%, respectively; p <
0.001)  
• Most common AEs detected via 
14-day active follow-up were 
fever (2.89%) and local reac-
togenicity (1.88%)  
• No serious AE was observed 
Availability  • First licensed within Europe in 1983 
and in the USA in 1989 [93]  
• Licensed for sale in 26 countries 
worldwide [94]  
• Recommended by the WHO since 
2008 for the control of typhoid in 
endemic and epidemic settings [73]  
• Licensed in the USA in 1994 [73]  
• Licensed in over 100 countries [95]  
• Recommended by the WHO since 
2008 for the control of typhoid in 
endemic and epidemic settings [73]  
• Licensed in India in 2013 [96] 
and Nepal [97]  
• Attained WHO prequalification 
status in 2018 [97]  
• Licensed in India in 2008 [73] 
ΔInjection site pain was statistically significant, p = 0.0499 [85]. 
Abbreviations: CI, confidence interval; AE, adverse event; S. Typhi, Salmonella enterica subspecies enterica serovar Typhi; WHO, World Health Organization. 
a The four dose regimen was registered in the USA and Canada in 1987 as a result of the study by Ferreccio and colleagues [81]. 
b Note that information from three additional studies has been excluded as the formulation, dose regimen or time interval between doses does not reflect those in 
current recommendations. Black and colleagues evaluated the efficacy of one or two doses of Ty21a in a randomised placebo-controlled field study in >80,000 children 
in Santiago, Chile [102]. Simanjuntak and colleagues evaluated three doses at weekly intervals [98]. Wahdan and colleagues evaluated a liquid formulation in <30, 
000 children in Egypt [99]. 
c Reference [83] states ages 5–16, reference [84] states ages 5–15. 
d Efficacy for one dose not reported. 
e Indirect herd protection has been demonstrated for Typherix® (GlaxoSmithKline), a Vi polysaccharide vaccine [103,106]. Typherix has been withdrawn in some 
countries [107,108]. 
f This can be used from 3 years of age according to technical data, however as the user has to be able to swallow the whole capsules it is recommended from 5 years of 
age. 
g Adverse events for the vaccine when given alone (not in combination with any other vaccine). 
h This monograph includes data from 2 clinical trials [84,100] as well as data held on file by Sanofi Pasteur. 
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pain [90]. Of 38 million immunisations administered between 1990 and 
2000, the total number of spontaneously reported adverse drug re-
actions was 0.001954% (i.e. ~20 in every million immunisations will 
result in an adverse drug reaction) [123]. 
During the early pre-licensure field trials in Chile, there was a 
considerable level of paratyphoid fever due to S. Paratyphoid B, allow-
ing estimation of cross-protection. The Ty21a vaccine has also been 
shown to confer moderate protection against S. Paratyphi B (efficacy 
49%) [89]. A randomised double-blind field trial of 20,543 subjects in 
Plaju, Indonesia (one dose per week for 3 weeks) suggests that Ty21a 
does not offer cross-protection against S. Paratyphi A [98]. 
5.2. Vi polysaccharide vaccine 
ViPS vaccines are based on the purified capsular polysaccharide, S. 
Typhi Vi antigen [11]. The Vi antigen of S. Typhi is well recognised as a 
factor for virulence and as an antigen that confers immunity against the 
typhoid fever [124]. The ViPS induces T cell-independent immune re-
sponses against S. Typhi, thus resulting in a lack of prolonged protection 
[97]. 
Evidence of the efficacy of ViPS vaccines comes from studies that 
utilised vaccines from two different manufacturers, TYPHIM Vi® 
(Table 1) and Typherix® (GlaxoSmithKline) vaccines. Typherix vaccine 
is no longer commercialised in some countries and may be unavailable 
for use [107,108]. Early pre-licensure randomised studies demonstrated 
that ViPS vaccines offer a moderate level of protection. A Nepalese study 
of TYPHIM Vi in subjects aged 5–44 years reported a total efficacy 
(blood culture proved and clinically suspected) of 75% [82]. A 
double-blind randomised trial of TYPHIM Vi in South African school 
children aged 5–15 years reported an efficacy of 55% [84]. A 
meta-analysis of four individually randomised clinical trials (including 
the two studies mentioned above plus two additional trials in China 
utilising locally produced ViPS) demonstrated efficacy of 69% (95% CI 
63–74) in year 1 (three trials) and 59% (95% CI 45–69) in year 2 (four 
trials) [11]. 
Subgroup analysis by age in a cluster-randomised trial conducted in 
India using Typherix post-licensure showed the efficacy as: 80% (95% CI 
53–91) in children under 5 years; 56% (95% CI 18–77) in those aged 
5–14 years; and 46% (95% CI -43–79) in those aged ≥15 and above 
[103]. To the contrary, a cluster-randomised trial conducted in Pakistan 
showed no protection among children aged 2–4 years (efficacy − 38% 
[95% CI -192− 35]) and 57% (95% CI 6–81) for children 5–16 years old 
[125]. 
An outbreak of typhoid fever in previously vaccinated French sol-
diers stationed in Cote d’Ivoire revealed that an interval of >3 years 
from the time of vaccination may result in reduced immunity [126]. 
Hypo-responsiveness or immunotolerance to re-vaccination is the 
inability of an individual to mount an immune response equal or greater 
than the immune response induced by primary vaccination [127]. This 
phenomenon has been described for polysaccharide vaccines [127]. 
Roggelin and colleagues assessed the influence of previous vaccinations 
with a ViPS (not more than 5 years ago) on post-vaccination antibody 
concentrations [128]. Thirty-six of the participants had been vaccinated 
once, nine had been vaccinated at least twice. There was no evidence of 
immunotolerance with multiple versus primary vaccination using a ViPS 
vaccine. However this was a small study, and the subgroup of those who 
had been previously vaccinated once showed the highest 
post-vaccination geometric mean antibody concentration compared 
with those who had been vaccinated twice before or received their 
primary vaccination [128]. 
A post-licensure cluster randomised trial in Kolkata, India, indicated 
that Typherix offers herd immunity. Among unvaccinated members of 
the vaccine clusters (geographical units that served as units of ran-
domisation), the level of protection was 44% (95% CI 2–69, model based 
on 25,083 subjects) [103]. 
ViPS vaccines, because of their poor immunogenic and T cell- 
independent properties, are not suitable for immunisation of infants 
[112]. ViPS vaccines are safe and recommended for HIV-infected in-
dividuals [73,121], however elicitation of protective antibodies is 
directly correlated with the levels of CD4+ T cells and thus the propor-
tion of individuals with protective antibody concentrations will be lower 
than in healthy controls [129]. Antibody responses are severely 
impaired in those with CD4 <200 cells/μL [129]. 
ViPS vaccines can be co-administered with other vaccines, including 
inactivated or attenuated, which is relevant for international travellers 
and routine childhood vaccination schedules [73]. As previously 
mentioned, there are no data on the safety of typhoid vaccines in 
pregnant women [122] and thus the manufacturer of TYPHIM Vi rec-
ommends that it should only be administered if clearly required and 
following risk assessment [75]. 
Post-marketing surveillance data collected in the USA through the 
Vaccine Adverse Event Reporting System (July 1990 to June 2002) 
revealed 321 reports of adverse events related to the administration of 
TYPHIM Vi alone or in combination with other vaccines [90]. The rate of 
AEs or serious AEs was 4.5 or 0.34 per 100,000 doses, respectively [90]. 
Common AEs included fever, headache and dizziness [90]. Serious side 
effects were rare [90]. 
Neither S. Paratyphi A or B express the Vi capsular antigen therefore 
there is no biological plausibility for cross-protection [27]. Theoreti-
cally, ViPS should offer protection against S. Paratyphi C, which does 
express the Vi capsular polysaccharide, although this is a rare cause of 
enteric fever and no data from field trials have reported protection [27]. 
5.3. Typhoid conjugate vaccines 
TCVs combine the Vi-polysaccharide capsule with a protein carrier 
[85]. For example, each dose of PedaTyph contains 5 μg of Vi poly-
saccharide of S. Typhi conjugated to 5 μg of tetanus toxoid [91], a re-
combinant inactive form of tetanus toxin produced by Clostridium tetani 
[97]. Covalently conjugating ViPS to carrier proteins overcomes the 
limitation of the ViPS vaccine by changing the immune response from T 
cell-independent to T cell-dependent, enabling immunisation even in 
young children [97]. Several conjugate subunit vaccines combining 
ViPS with another protein antigen (typically inactive forms of bacterial 
exotoxins) are under investigation [97]. At present, hyporesponsiveness 
is not thought to be a feature of repeated vaccination with conjugate 
vaccines [127]. Limited data are currently available – large field studies 
are required and further investigations are being conducted by the 
Typhoid Vaccine Acceleration Consortium [130]. 
Since TCVs are less well established for typhoid vaccination, data are 
comparatively limited. A Phase 2b randomised controlled trial showed 
that the efficacy of Typbar-TCV was 54.6% in a controlled human 
infection model of typhoid fever in adult volunteers aged from 18 to 60 
years; a post hoc analysis of these data revealed that if alternative 
diagnostic criteria were applied, such as fever of 38.0 ◦C or higher fol-
lowed by bacteraemia, the estimated efficacy would be 87.1% [85]. In a 
report of two trials (randomised controlled and an open-label trial), 
adverse events for Typbar-TCV were uncommon [92]. Fever was the 
most common, with 4.3% (14/340) of subjects experiencing this AE 
[92]. Post-marketing surveillance data reported fever, pain and swelling 
in 1–10% of vaccinees in any age group (no serious AEs were reported) 
[131]. Whether Typbar-TCV offers herd immunity is unknown at pre-
sent, however herd immunity has been observed with other conjugate 
vaccines due to mucosal immunity and will need to be addressed in 
future studies. 
The efficacy of PedaTyph was determined in a single cluster open- 
label randomised control trial in 950 children aged 6 months to 12 
years: year 1 efficacy was reported to be 100% (95% CI 97.6–100) [86]. 
A study of 400 children to assess the safety and immunogenicity of 
PedaTyph reported non-severe AEs in 17% of children with one dose, 
recoverable within 48 h [91]. At present, there is no evidence of inter-
ference with other vaccines (e.g. the trivalent measles, mumps and 
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rubella vaccine) [122]. Although there are no data to this effect, like the 
ViPS vaccine, it is not biologically plausible for cross-protection to be 
induced against S. paratyphoid A and B. Theoretically, cross-protection 
against S. paratyphoid C is possible. 
5.4. Other typhoid conjugate vaccines 
There are several other typhoid vaccines available, or in the devel-
opment pipeline, that utilise a variety of carrier proteins. Vi-rEPA, Vi 
polysaccharide bound to the recombinant exoprotein of Pseudomonas 
aeruginosa, showed efficacy of >90% in a Phase 3 study of Vietnamese 
children aged 2–5 years [132] and will be available in China soon [133]. 
Vi-CRM197, Vi polysaccharide conjugated with CRM197 (a non-toxic 
mutant of diphtheria toxin), has completed Phase 2 trials in infants, 
children and adults [134] and is in clinical development [135]. Vi-DT 
vaccine, Vi polysaccharide conjugated to diphtheria toxoid, is 
currently undergoing assessment in a Phase 2 trial in children ages 3–23 
months [136]. A Phase 3 trial in children and adults is due to complete in 
January 2020 [137]. In a Phase 1 study in adults aged 18–40 years old 
and children aged 2–5 years old [138], and in Phase 2 studies in children 
aged 6 to ≤24 months [139,140], the Vi-DT vaccine has been shown to 
be well tolerated and immunogenic. 
In summary, there are several vaccines available for the prevention 
of typhoid, the choice of which will include factors such as the local 
availability and age of the intended recipient. 
6. Vaccination strategies 
A combined approach to typhoid health security based on public 
health that includes the use of typhoid vaccines, improvements in 
sanitation and safe water supply is necessary [141]. Vaccination has the 
potential to decrease the use of antibiotics, limit the emergence of 
resistant S. Typhi strains and create a herd immunity. Consequently, it 
should be offered to those who reside in endemic regions as well as to 
travellers to destinations where antibiotic-resistant strains of S. Typhi 
are prevalent [142]. As it is difficult to obtain the output from moni-
toring and reporting information in real time, and because typhoid fever 
may not have the highest priority due to competition from other diseases 
with higher morbidity/mortality, vaccination should be offered irre-
spective of the intensity of other control strategies [142]. 
Feedback from regions and countries on the implementation of the 
Strategic Advisory Group of Experts recommendations on typhoid 
identified that, as the incidence of S. Typhi declines, there has been a 
concomitant rise in the incidence of S. Paratyphi [143]. This increases 
the uncertainty of the value of typhoid vaccination in the absence of a 
vaccine against S. Paratyphi. In this context, vaccines that offer 
cross-protection against S. Paratyphi (Ty21a for example) may be 
considered to be of greater value. 
6.1. Global recommendations for vaccination in endemic areas 
The WHO currently recommend vaccination, using Ty21a, ViPS or 
TCV, to control endemic typhoid fever and outbreaks. The WHO rec-
ommends TCV in all ages due to its improved immunological properties, 
suitability for use in younger children and expected longer duration of 
protection [73]. Use of ViPS vaccine in individuals aged ≥2 years, and 
Ty21a vaccine for individuals aged >6 years, is also suitable [73]. 
6.1.1. Strategies for the introduction of typhoid vaccines 
Routine typhoid fever vaccination for public health use has been very 
limited in the past, even in endemic areas, hampered by the lack of an 
effective vaccine for young children and relatively short duration of 
protective efficacy [144–146]. Typbar-TCV attained WHO 
pre-qualification in 2017 so the current landscape of typhoid vaccine 
usage is set to change (see Section 6.1.2, “Stakeholders in typhoid vac-
cine programmes”) [147]. The introduction of TCVs should be 
prioritised in countries with the highest burden of typhoid disease or a 
high burden of antimicrobial resistant S. Typhi [73]. Data from Breiman 
and colleagues showed a high disease burden in densely populated 
urban slums compared with a low incidence in rural areas, supporting a 
typhoid immunisation strategy with a geographically and environmen-
tally targeted approach [148]. 
Studies are ongoing to demonstrate whether the programmed 
introduction of an effective typhoid vaccine into countries with high 
burden of disease or significant antimicrobial resistance could have a 
dramatic impact, protecting children from infection and reducing anti-
microbial usage [149]. Health-economics and cost-effectiveness studies 
suggest that vaccination (using a TCV) is likely highly cost-effective in 
high-burden settings (>100 cases per 100,000 population) [49]. An 
age-structured transmission and cost-effectiveness model that simulated 
multiple vaccination strategies with a TCV showed that TCVs would be 
highly cost-effective in low-income countries in settings of moderate 
typhoid incidence (50 cases/100,000 annually) [150]. 
In countries with epidemiological evidence of high incidence in well- 
defined subpopulations, a vaccination strategy based on risk assessment 
should be considered [142]. An evaluation of the cost-effectiveness of 
ViPS vaccination against typhoid in multiple Asian sites demonstrated 
that a vaccination programme targeting children would be “very cost--
effective” (e.g. costs per disability-adjusted life-years averted less than 
per-capita gross national income), but programmes that also target 
adults are less cost-effective (albeit due to the lower incidence in adults 
than children) [151]. Recent cost-effectiveness analysis in five endemic, 
low- and middle-income settings showed that routine vaccination with 
TCVs, as well as one-time catch-up campaigns, would be cost-effective in 
most settings [152]. 
A recent study has modelled the predicted impact of TCVs on anti-
microbial resistance, using the relative fitness of the resistant strain(s), 
prevalence of chronic carriers, and rates of recovery without treatment 
as variables. Notably, herd immunity was not included in the model. The 
study found that increasing vaccination coverage would decrease the 
total number of antimicrobial-resistant typhoid infections but not affect 
the proportion of cases that were antimicrobial resistant [153]. Further 
evaluation in real-world typhoid-endemic settings is necessary to 
confirm the model’s predictive results. However, in low-resource set-
tings (where typhoid is endemic), there is little chance of being able to 
confirm these results. As such, the likely impact of TCVs on antimicro-
bial resistance remains to be determined. 
As asymptomatic carriers are thought to be responsible for mainte-
nance of S. Typhi in the human population, a strategy for reducing this 
reservoir could be of interest. Stratification of carriers by age could 
support the vaccination strategy in endemic countries. 
Interestingly, concomitant administration of Ty21a and ViPS has 
also been explored [154]. The enhanced immune response observed 
suggests that usage in this manner should elicit higher protective effi-
cacy, although this is still to be investigated. The authors suggest that 
concomitant use should be encouraged for those at significant risk 
[154]. 
Recent findings from Bhutta and colleagues, studying surveillance 
data from several countries, documented substantial reductions in 
typhoid fever burden over recent decades which may be associated with 
improvements in economic conditions, education and environmental 
health [155]. It is likely that public health programmes of vaccination 
could also impact the burden of disease, as has been seen with other 
pathogens. However, it is possible that differing patterns of urbanisa-
tion, and resultant population densities, could impact on the success of 
vaccination strategies. 
Like typhoid, cholera is a bacterium transmitted by faecally 
contaminated water and it has a high burden of disease, predominantly 
in areas that lack access to safe water [156]. In 2011, the first low-cost 
oral cholera vaccine obtained WHO pre-qualification status and efforts 
began to stockpile the vaccine for use in endemic and epidemic settings 
[157]. There were operational challenges that hampered the subsequent 
C. Masuet-Aumatell and J. Atouguia                                                                                                                                                                                                       
Travel Medicine and Infectious Disease 40 (2021) 101946
10
vaccination campaigns, including regulatory hurdles, cold chain logis-
tics, and vaccine coverage and uptake, however from 2011 to 2015, 4.8 
million doses of cholera vaccine were administered globally [157]. 
Whilst it may be too early to assess the impact of these vaccinations, 
surveillance data from Malawi has shown that cholera outbreaks were 
absent in vaccinated high-risk areas (despite a national outbreak during 
the surveillance period), suggesting the suitability of this approach 
[158]. Vaccines have been used with great effect for other endemic 
diseases, such as polio. Since 1988, when the sustained use of polio 
vaccines began, the number of countries with endemic polio has reduced 
from 125 to just two in 2015 (Afghanistan and Pakistan) [93]. Concerted 
and sustained efforts concerning typhoid vaccinations might similarly 
result in substantial reductions in the decades to come. 
6.1.2. Stakeholders in typhoid vaccine programmes 
Several global activities support the introduction of vaccines, with 
efforts ongoing to make new typhoid vaccines available and accessible 
to those that need them. 
As part of their vaccine investment strategy, Gavi, the Vaccine Alli-
ance, prioritised typhoid vaccines in 2008 but did not make a financial 
commitment at that time [147]. All vaccines supported by Gavi are 
supplied through the United Nations procurement process and so 
pre-qualification is necessary for purchase and subsequent introduction 
into Gavi-eligible countries [159]. Following the WHO pre-qualification 
of the TCV vaccine Typbar-TCV in 2017 [147], Gavi approved US$85 
million in funding to support eligible countries to introduce TCVs [160]. 
At present, there are 58 countries eligible for Gavi funding – to be 
eligible, a country’s gross national income per capita must be ≤US 
$1580 over the previous 3 years [161]. A country’s Gavi-eligibility 
status may have a large influence on a country’s vaccine introduction 
decision and the introduction of TCVs may be more difficult in 
Gavi-ineligible countries [162]. 
The Coalition against Typhoid was created with the aim of pre-
venting typhoid among vulnerable populations through research, edu-
cation and advocacy [163]. The Typhoid Vaccine Acceleration 
Consortium aim to facilitate the introduction of TCVs into Gavi-eligible 
countries to reduce the burden of typhoid using an integrated, proactive 
approach [164]. Through the efforts of these groups and others, progress 
towards the reduction in typhoid fever is being made. 
6.2. Recommendations for travellers to high-risk areas 
For individuals in non-endemic areas, typhoid fever impacts travel-
ling populations such as tourists, military personnel, or travellers VFR in 
endemic areas. Travel destination is the main factor for assessing the risk 
of acquiring typhoid fever [36]. Other factors include area of stay, 
duration of stay, purpose of travel and type of accommodation [36]. 
There are also risk factors intrinsic to the traveller, including age and 
diagnosed/undiagnosed underlying medical conditions [36]. In those 
travellers with impaired immunity (e.g. HIV), vaccination is less effec-
tive [129]. 
Vaccination has the potential to decrease the use of antibiotics (both 
standby and therapeutic use) and limit the emergence of resistant S. 
Typhi strains, and should be offered to travellers to destinations where 
Table 2 
General vaccine recommendations to prevent typhoid fever for travellers to selected middle and high incidence typhoid fever countries [94,171–188] (inci-
dence as per [14]). 
Risk factor codes: A. Children; B. VFR; C. Extended/longer duration of stay; D. Existing illness/medical condition; E. Poor hygiene conditions/sanitation; F. 
Increased exposure (e.g. cooperative trips, backpacking, trekking); G. Duration of stay (>4 weeks); H. Activities; I. Visiting small cities/rural areas; J. Contact 
with the local population; K. Duration of stay (>3 weeks); L. Poor food hygiene; M. Frequency of stays; N. Adventurous eating; O. Duration of stay; P. 
Circumstance of stay; Q. Duration of stay (>1 week). 
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antibiotic-resistant strains of S. Typhi are prevalent [142]. This is 
particularly important given that standby antibiotics encourage less 
cautious use of antibiotics [165]. One of the available licensed products 
should be offered, namely Ty21a, ViPS or TCV. Licensed combination 
unconjugated ViPS-hepatitis A vaccines, where available, may also be 
used for travellers [73]. 
There is relatively little evidence of the effect of vaccinations in 
preventing typhoid in travellers who have visited typhoid-endemic 
areas. Data from 4 years of US national surveillance reported by 
Mahon and colleagues showed moderate protection (80%) from typhoid 
fever in vaccinated US travellers who travelled to southern Asia [166]. 
As the vaccination information gathered from reports did not specify the 
vaccine administered, the effectiveness of each individual vaccine could 
not be estimated. In the UK, between 2007 and 2012, >99% of typhoid 
vaccines prescribed were ViPS vaccines (TYPHIM Vi, Typherix, Hep-
atyrix® or VIVAXIM®) [167]. In travellers from England (children ≥2 
years and adults) the overall effectiveness of typhoid ViPS vaccines was 
65% (95% CI 53–73) [167]. 
In Canada, the Committee to Advise on Tropical Medicine and Travel 
suggest that typhoid vaccine (Ty21a or ViPS) be used for Canadian 
travellers visiting South Asia [168]. In the UK, the National Travel 
Health Network and Centre generally recommend vaccination for most 
travellers to typhoid-endemic countries where there is a “medium” 
disease incidence and the access to improved sanitation is <80% [169]. 
In the USA, guidelines were updated in 2015, and continue to recom-
mend vaccination for travellers to certain countries, close contacts of 
chronic carriers, and certain laboratory workers [170]. 
At present, recommendations worldwide are not harmonised and can 
be generic or tailored for risk groups (Table 2). Experts must assess 
vaccination of travellers based on current country-specific recommen-
dations and travel characteristics. Regardless of the incidence rate of 
typhoid in individual countries, European countries have different 
vaccination recommendations for travellers to those countries, with the 
need for vaccination based on travel duration, travel destination, cir-
cumstances of travelling or a combination of these factors. 
Interviews with staff members from migrant resource centres have 
revealed that, paradoxically, migrants may believe that they are at lower 
risk than non-VFR travellers [34]. This is in part due to a generalised 
perception of immunity that they hold [34]. Efforts should be increased 
to target this sub-group of travellers. 
As typhoid vaccines do not offer complete protection, safe water, 
sanitation and hygiene interventions are critical to preventing the 
spread of typhoid, both in endemic settings and among travellers [189]. 
A multidisciplinary strategy of public health based on personal protec-
tion and infrastructure interventions is needed. 
7. Conclusion 
Resistance has become a major threat to the treatment of typhoid, 
leading to treatment failure and subsequent changes in antimicrobial 
policy. The increasing prevalence of MDR S. Typhi strains is an impor-
tant factor in the development of vaccination strategies for the preven-
tion of typhoid infection in high-risk populations. The use of TCVs in 
endemic regions may be the best defence against MDR S. Typhi [54]. 
There is a need for worldwide surveillance and access to information on 
resistant strains, parallel to improvements in antibiotic usage and 
stewardship. 
Country-level decision-making and programme planning are critical 
for local uptake and sustainability of vaccination strategies [122]. Na-
tional decisions on the preferred vaccination strategy should be based on 
an analysis of the disease burden and risk factors for transmission, 
availability and quality of surveillance data, affordability, and opera-
tional feasibility. In parallel to vaccination, efforts to improve sanitation 
should continue. 
For travellers, harmonisation of recommendations is likely to be of 
benefit. In particular, greater effort should be made to encourage 
vaccination for those visiting family and friends. 
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